SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Corbus Pharmaceuticals Holdings, Inc. (CRBP) News

Follow Corbus Pharmaceuticals Holdings, Inc. (CRBP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CRBP Asset equity Sector Markets 90 days 7 Last 2.06 Updated Nov 16, 2026, 01:02 PM UTC Open live news feed Open CRBP chart & news
M Corbus Reports 5% Mean Weight Loss at 60 mg in Phase 1b Study Corbus said all three CRB-913 doses in its Phase 1b CANYON-1 study produced statistically significant weight loss. The 60 mg dose achieved mean weight loss of 5% at 12 weeks; adverse-event-related discontinuation across EQUITY | Nov 16, 2026, 01:02 PM UTC M Corbus Pharmaceuticals Q3 Results Expected November 10 Corbus Pharmaceuticals is expected to report Q3'26 results on November 10. Revenue is estimated at $1.67 million and EPS at $(1.27); the release time is not specified. EQUITY | Nov 09, 2026, 12:01 PM UTC L Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infectionOPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 NEWS | Sep 29, 2026, 12:09 PM UTC M Corbus Pharmaceuticals doses first patient in TEMPO-1 for CRB-701 Corbus Pharmaceuticals announced the first patient was dosed in its TEMPO-1 registrational study of CRB-701 in patients with 2L+ oropharyngeal cancer. EQUITY | Sep 29, 2026, 12:03 PM UTC L Corbus Pharmaceuticals Stock Surges Ahead of Drug Data Readout By Kelly CloonanShares of Corbus Pharmaceuticals rallied after the company said it would host a webcast to discuss topline data for a study for an obesity treatment.The stock was up 20% to $9.75 in late trading on Friday EQUITY | Sep 11, 2026, 09:28 PM UTC L Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDTNORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP, a clinical-stage company focused on developing ne NEWS | Sep 11, 2026, 08:02 PM UTC L CRBP - Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity CRBP - Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity NEWS | Sep 11, 2026, 08:01 PM UTC L Corbus (CRBP) reports inducement grants under Nasdaq Rule 5635(c)(4) Corbus (CRBP) reports inducement grants under Nasdaq Listing Rule 5635(c)(4), per the company disclosure, with no additional terms or amounts provided in the feed. REGULATION | Aug 17, 2026, 02:00 PM UTC L CRBP - Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update CRBP - Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update EARNINGS | Aug 06, 2026, 12:00 PM UTC M Corbus Pharmaceuticals Completes CANYON-1 Study Corbus completes obesity treatment study EQUITY | Aug 04, 2026, 12:31 PM UTC L Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial Corbus Pharmaceuticals... EQUITY | Jul 28, 2026, 01:12 PM UTC L CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal ca CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal cancer Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registra REGULATION | Jul 28, 2026, 12:00 PM UTC L Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( EQUITY | Jul 06, 2026, 12:01 PM UTC